ArticleBritish journal of cancer1999
Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers.
Article in British journal of cancer, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Interactions between CYP1A1 polymorphisms and cigarette smoking are associated with the risk of hepatocellular carcinoma: evidence from epidemiological studies.Molecular biology reports · 2012Pooled it
- GST polymorphisms are associated with hepatocellular carcinoma risk in Chinese population.World journal of gastroenterology · 2011Pooled it
- Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients.World journal of gastroenterology · 2004Trial
- Cross-Species Upregulation ofCurrent issues in molecular biology · 2026Article
- Cloning and Functional Characterization of a Novel Brevinin-1-Type Peptide fromCurrent issues in molecular biology · 2025Article
- A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients.IET systems biology · 2022Article
- Cytochrome P450 Genes (CYP2E1 and CYP1A1) Variants and Susceptibility to Chronic Hepatitis B Virus Infection.Indian journal of clinical biochemistry : IJCB · 2018Article
- The Interaction of Smoking with Gene Polymorphisms on Four Digestive Cancers: A Systematic Review and Meta-Analysis.Journal of Cancer · 2018Article
- Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma.BioMed research international · 2018Article
- The Identification of Core Gene Expression Signature in Hepatocellular Carcinoma.Oxidative medicine and cellular longevity · 2018Article
- Are CYP1A1 polymorphisms associated with the risk of hepatocellular carcinoma?Molecular biology reports · 2013Article
- Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.World journal of hepatology · 2010Article
- Impact of hepatitis C virus infection on lifestyle.World journal of gastroenterology · 2007Article
- Heavy smoking and liver.World journal of gastroenterology · 2006Review
- Identification of CYP2C9*2 allele in HepG2 cell line.International journal of gastrointestinal cancer · 2006Article
- Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance.World journal of gastroenterology · 2002Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Cigarette smoking has been associated with increased risk of hepatocellular carcinoma (HCC) in some epidemiological studies. Cytochrome P450 1A1 (CYP1A1) is involved in the biotransformation of tobacco-derived polycyclic aromatic hydrocarbons (PAHs) into carcinogenic metabolites. The aim of this study was to determine whether CYP1A1 polymorphisms were related to HCC risk among chronic hepatitis B virus (HBV) carriers. Genotypic variants of CYP1A1 were determined using polymerase chain reaction in 81 incident cases of HCC and 409 controls nested in a cohort study of 4841 male chronic HBV carriers. No overall association between CYP1A1 genotypes and HCC was observed. The presence of the Mspl (odds ratio (OR) 3.15, P = 0.0196) or Ile-Val (OR 1.99, P = 0.0855) variant allele of CYP1A1 increased HCC risk among smokers, but posed no increased risk among non-smokers. The smoking-related HCC risk was most pronounced among those who had a susceptible allele of the CYP1A1 and a deficient genotype of glutathione S-transferase M1, which detoxifies PAH electrophilic metabolites produced by CYP1A1. In the absence of the Ile-Val variant allele, the Mspl polymorphism was still associated with smoking-related HCC. This study suggests that tobacco-derived PAHs play a role in HCC risk among chronic HBV carriers, and CYP1A1 polymorphism is an important modulator of the hepatocarcinogenic effect of PAHs. The Mspl and Ile-Val polymorphisms of CYP1A1 may have different mechanisms for increasing susceptibility to smoking-related HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.